HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rajendran, J. G. Articles by Fritzberg, A. Search for Related Content PubMed PubMed Citation Articles by Rajendran, J. G. Articles by Fritzberg, A.

High-Dose ¹⁶⁶Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation

¹ Department of Radiology, University of Washington, Seattle, Washington
² Fred Hutchinson Cancer Research Center, Seattle, Washington
³ NeoRx Corporation, Seattle, Washington

Thirty-two patients with multiple myeloma were treated with high doses of ¹⁶⁶Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid (DOTMP) and were a subset of patients enrolled in a multicenter phase I/II dose escalation myeloablative trial. ¹⁶⁶Ho with ß-emission (half-life, 26.8 h; ß-particle energies, 1.85 MeV [51%] and 1.77 MeV [48%]; -photons, 80.6 keV [6.6%] and 1.38 MeV [0.9%]) was complexed to DOTMP, a macrocyclic tetraphosphonate. Pharmacokinetics, dosimetry, and biodistribution were studied. Methods: Patients were treated at escalating dose levels of 20, 30, and 40 Gy to the bone marrow in combination with high-dose melphalan, with or without total-body irradiation, to evaluate toxicity and efficacy. After infusion with 1,110 MBq (30 mCi) of ¹⁶⁶Ho-DOTMP for evaluation of biodistribution and dosimetry calculation, patients received the calculated amount of radioactivity for therapy in a single administration based on estimated dose calculations. Results: Thirty-two patients participated in the study and were then treated. The average amount of administered radioactivity was 74.3 GBq (2,007 mCi) (range, 21.5–147.5 GBq [581–3,987 mCi]) of ¹⁶⁶Ho-DOTMP. Conclusion: ¹⁶⁶Ho-DOTMP has physical and pharmacokinetic characteristics compatible with high-dose myeloablative treatment of multiple myeloma.

Key Words: ß-emitters • radionuclide therapy • myeloablation • dosimetry • myeloma

This article has been cited by other articles:

				J. G. Rajendran, A. K. Gopal, D. R. Fisher, L. D. Durack, T. A. Gooley, and O. W. Press Myeloablative 131I-Tositumomab Radioimmunotherapy in Treating Non-Hodgkin's Lymphoma: Comparison of Dosimetry Based on Whole-Body Retention and Dose to Critical Organ Receiving the Highest Dose J. Nucl. Med., May 1, 2008; 49(5): 837 - 844. [Abstract] [Full Text] [PDF]

				H. B. Breitz, R. E. Wendt III, M. S. Stabin, S. Shen, W. D. Erwin, J. G. Rajendran, J. F. Eary, L. Durack, E. Delpassand, W. Martin, et al. 166Ho-DOTMP Radiation-Absorbed Dose Estimation for Skeletal Targeted Radiotherapy J. Nucl. Med., March 1, 2006; 47(3): 534 - 542. [Abstract] [Full Text] [PDF]

				J. G. Rajendran, D. R. Fisher, A. K. Gopal, L. D. Durack, O. W. Press, and J. F. Eary High-Dose 131I-Tositumomab (Anti-CD20) Radioimmunotherapy for Non-Hodgkin's Lymphoma: Adjusting Radiation Absorbed Dose to Actual Organ Volumes J. Nucl. Med., June 1, 2004; 45(6): 1059 - 1064. [Abstract] [Full Text] [PDF]